{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:57:38Z","timestamp":1790614658118,"version":"4.1.0"},"reference-count":29,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2021,8,15]],"date-time":"2021-08-15T00:00:00Z","timestamp":1628985600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To investigate once\u2010weekly (OW) semaglutide, a glucagon\u2010like peptide\u20101 receptor agonist (GLP\u20101RA), in patients with type 2 diabetes (T2D) in routine clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The SURE Canada study was a multicenter, prospective, observational study. Adults with T2D and one or more documented HbA1c values 12\u2009weeks or less before semaglutide initiation were enrolled. The primary endpoint was change in HbA1c from baseline to end of study (EOS; ~30\u2009weeks). Secondary endpoints included change in body weight (BW), waist circumference and patient\u2010reported outcomes (PROs) and the proportion of patients achieving HbA1c of less than 7.0%, weight loss (WL) of 5% or higher, and a composite of HbA1c reduction of 1% or higher and WL of 3% or higher at EOS. Data were analysed and presented for patients on semaglutide at EOS overall and for the following baseline medication subgroups: oral antihyperglycaemic drugs (OADs) only; GLP\u20101RA experienced; insulin\u2009\u00b1\u2009OADs without GLP\u20101RA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 452 patients initiated semaglutide and 356 completed the study on treatment. For the 452 patients, mean baseline HbA1c was 8.1%; 86 (19.0%) patients had HbA1c of less than 7.0%. Mean dose of semaglutide at EOS was 0.76\u2009\u00b1\u20090.31\u2009mg. Mean HbA1c was reduced by 0.9%\u2010point (95% confidence interval [CI]: 0.97; 0.78). Mean BW was reduced by 4.3\u00a0kg (95% CI: 4.79; 3.76). At EOS, 46.9% of patients achieved HbA1c of less than 7.0%, 40.9% achieved WL of 5% or higher and 24.1% achieved the composite endpoint. PROs improved from baseline to EOS. No new safety concerns were reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In SURE Canada, patients treated with OW semaglutide in routine clinical practice experienced clinically significant improvements in HbA1c, BW and other outcomes, supporting semaglutide use in routine clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.14468","type":"journal-article","created":{"date-parts":[[2021,6,18]],"date-time":"2021-06-18T00:42:55Z","timestamp":1623976975000},"page":"2269-2278","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Use of once\u2010weekly semaglutide in patients with type\n                    <scp>2<\/scp>\n                    diabetes in routine clinical practice: Results from the\n                    <scp>SURE C<\/scp>\n                    anada multicentre, prospective, observational study"],"prefix":"10.1111","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7833-9050","authenticated-orcid":false,"given":"Jean\u2010Fran\u00e7ois","family":"Yale","sequence":"first","affiliation":[{"name":"McGill University Health Centre  Montreal Quebec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei\u2010Mircea","family":"Catarig","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S  S\u00f8borg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrine","family":"Grau","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S  S\u00f8borg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stewart","family":"Harris","sequence":"additional","affiliation":[{"name":"Schulich School of Medicine and Dentistry Western University  London Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Klimek\u2010Abercrombie","sequence":"additional","affiliation":[{"name":"Novo Nordisk Canada Inc.  Mississauga Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4706-5170","authenticated-orcid":false,"given":"R\u00e9mi","family":"Rabasa\u2010Lhoret","sequence":"additional","affiliation":[{"name":"Lotus Health Clinic  Halifax Nova Scotia Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Reardon","sequence":"additional","affiliation":[{"name":"Montreal Clinical Research Institute  Montreal Quebec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Woo","sequence":"additional","affiliation":[{"name":"St Boniface Hospital  Winnipeg Manitoba Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Liutkus","sequence":"additional","affiliation":[{"name":"Joanne F. Liutkus Medicine Professional Corporation  Cambridge Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,8,15]]},"reference":[{"key":"e_1_2_9_2_1","volume-title":"IDF Diabetes Atlas","author":"International Diabetes Federation","year":"2019"},{"key":"e_1_2_9_3_1","unstructured":"Public Health Agency of Canada.Diabetes in Canada: Highlights from the Canadian Chronic Disease Surveillance System.http:\/\/publications.gc.ca\/collections\/collection_2018\/aspc-phac\/HP35-94-2017-eng.pdf. Accessed 21 December 2020."},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.2337\/dci18-0033"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjd.2020.08.001"},{"key":"e_1_2_9_6_1","unstructured":"Novo Nordisk Canada Inc.Health Canada approves RYBELSUS\u00ae (semaglutide tablets) the first and only GLP\u20101 analogue in a pill for the treatment of adults with type 2 diabetes.https:\/\/www.newswire.ca\/news-releases\/health-canada-approves-rybelsus-r-semaglutide-tablets-the-first-and-only-glp-1-analogue-in-a-pill-for-the-treatment-of-adults-with-type-2-diabetes-814386455.html. Accessed 21 December 2020."},{"key":"e_1_2_9_7_1","unstructured":"Novo Nordisk Canada Inc.Ozempic\u00ae approved in Canada for the treatment of adults with type 2 diabetes.https:\/\/www.newswire.ca\/news-releases\/ozempic-approved-in-canada-for-the-treatment-of-adults-with-type-2-diabetes-668432133.html. Accessed 21 December 2020."},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30013-X"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30092-X"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-0417"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30085-2"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-00070"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30024-X"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30311-0"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30066-X"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2019.101117"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-018-0805-y"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.281053"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1471"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-7176.2008.07572.x"},{"issue":"1","key":"e_1_2_9_21_1","first-page":"59","article-title":"New medication adherence scale versus pharmacy fill rates in seniors with hypertension","volume":"15","author":"Krousel\u2010Wood MA","year":"2009","journal-title":"Am J Manag Care"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.02.023"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2017.1421146"},{"key":"e_1_2_9_24_1","doi-asserted-by":"crossref","unstructured":"LingvayI KirkA LophavenS WoldenML ShubrookJ.GLP\u20101\u2013experienced patients switching to once\u2010weekly semaglutide in a real\u2010world setting (EXPERT study). Poster 954\u2010P presented at the 81st American Diabetes Association Scientific Sessions virtual event; 25\u201029 June 2020.","DOI":"10.2337\/db20-954-P"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0138662"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14117"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-1974"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.13731"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2019.10.001"},{"key":"e_1_2_9_30_1","doi-asserted-by":"crossref","unstructured":"JainAB KantersS KhuranaR KissockJ SeverinN StaffordS.Real world efficacy analysis of switch from liraglutide or dulaglutide to semaglutide in type 2 diabetes mellitus: REALiSe\u2010DM study. Poster OP 0073 presented at the International Diabetes Federation Congress Busan Korea; 2\u20107 December 2019.","DOI":"10.1007\/s13300-020-00984-x"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.14468","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.14468","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.14468","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T04:34:36Z","timestamp":1761885276000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.14468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,15]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["10.1111\/dom.14468"],"URL":"https:\/\/doi.org\/10.1111\/dom.14468","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/DOM.14468\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14468\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14468\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14468\/v2\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14468\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14468\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14468\/v1\/decision1","asserted-by":"object"}]},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,15]]},"assertion":[{"value":"2021-03-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}